Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nxera Pharma CoFRA:JSS +2.92%76 Days Sales Outstanding is 111.35 as of Jun. 2026, which is 96% above its 10-year median of 56.87. GuruFocus rates FRA:JSS with a GF Score™ of 76/100 and a GF Value™ of €6.08. The stock has 9 warning signs investors should review. Among 840 Biotechnology companies, Nxera Pharma Co ranks worse than 63.57% on this metric.
Nxera Pharma Co (FRA:JSS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Nxera Pharma Co Days Sales Outstanding Related Terms
Nxera Pharma Co Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:JSS vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Nxera Pharma Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's Days Sales Outstanding falls into.
Nxera Pharma Co Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 111.35 mean?
Nxera Pharma Co (FRA:JSS) has a Days Sales Outstanding of 111.35 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nxera Pharma Co and its competitors. This is 96% above median its historical median of 56.87. Over the past decade, Nxera Pharma Co's Days Sales Outstanding has ranged from 14.28 to 107.59. According to the industry distribution chart, Nxera Pharma Co ranks #534 out of 840 companies in the Biotechnology industry, placing it in the top 63.6%.
Is Nxera Pharma Co's Days Sales Outstanding too high?
Nxera Pharma Co's current Days Sales Outstanding of 111.35 is 96% above median its 10-year median of 56.87. Over the past 10 years, this metric has ranged from a low of 14.28 to a high of 107.59. The Biotechnology industry median Days Sales Outstanding is 69.01. Nxera Pharma Co's value of 111.35 is 61.4% above this industry median. Based on the distribution chart, Nxera Pharma Co ranks #534 out of 840 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nxera Pharma Co has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #534 out of 840 companies for Days Sales Outstanding. This places Nxera Pharma Co in the lower half of its industry. The industry median Days Sales Outstanding is 69.01. Nxera Pharma Co's value of 111.35 is 61.4% above this benchmark. Historically, Nxera Pharma Co's own Days Sales Outstanding has ranged from 14.28 to 107.59 over the past decade. While the company's 10-year median is 56.87 vs. the industry median of 69.01, Nxera Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.01, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nxera Pharma Co's current Days Sales Outstanding of 111.35 is 61.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nxera Pharma Co and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nxera Pharma Co's current Days Sales Outstanding is 111.35, which is 96% above median its own 10-year median of 56.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Nxera Pharma Co (FRA:JSS) has a current Days Sales Outstanding of 111.35. The stock's GF Value™ is €6.08, compared to a current price of €7.05 — trading 16% above its estimated fair value. The current Days Sales Outstanding is 111.35, which is 96% above median its 10-year median of 56.87 and 61.4% above the Biotechnology industry median of 69.01. Nxera Pharma Co's overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Nxera Pharma Co (FRA:JSS), the current Days Sales Outstanding is 111.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued.
The current stock price of €7.05 is trading 16% above its estimated GF Value™ of €6.08.
Key valuation signals for FRA:JSS:
Days Sales Outstanding: 111.35 (96% above median its 10-year median of 56.87)
GF Value™: €6.08 vs. price of €7.05 (16% above fair value)
Industry Position: 61.4% above the Biotechnology median (#534 of 840)
No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
76GF Score
Get the complete analysis for FRA:JSS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JSS has been successfully added to your 
